Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company focused on light-activated antimicrobial therapies, announced on 17 November 2026 that the Journal of Hospital Infection has published a peer-reviewed study from the University of Ottawa Heart Institute linking the company's Steriwave nasal photodisinfection technology to a 52.8% relative reduction in conduit harvest surgical site infections across 2,172 consecutive coronary artery bypass graft procedures. The interrupted time series study also found that protocol compliance rose from 35.4% to 93.3% following the switch from topical antibiotic regimens to nurse-administered, point-of-care Steriwave treatment. The publication follows preliminary presentations at the Canadian Cardiovascular Congress and represents a significant body of real-world clinical evidence for Ondine's lead authorised product.
Key Points
- Ondine Biomedical Inc. (AIM: OBI) — Canadian life sciences company developing photodisinfection therapies authorised in Canada, the UK, and select international markets
- Journal of Hospital Infection publishes 32-month interrupted time series data from the University of Ottawa Heart Institute across 2,172 CABG procedures
- Conduit harvest surgical site infections fell from 3.6% to 1.7%; statistically significant in the primary model (RR 0.20, 95% CI 0.05–0.72; p=0.014); compliance rose from 35.4% to 93.3%
- Investors may be watching whether this peer-reviewed publication supports broader adoption of Steriwave in cardiac surgery settings and potential regulatory progress in new markets
32-Month UOHI Study Design: Mupirocin Baseline Versus Steriwave Intervention Across 2,172 CABG Cases
The published study analysed 32 months of consecutive CABG procedures at the University of Ottawa Heart Institute, Canada's largest cardiovascular health centre. The dataset comprised a 24-month mupirocin baseline era covering 1,678 patients and an 8-month Steriwave intervention era covering 494 patients. The study used an interrupted time series methodology, which the announcement states is a before-and-after comparison rather than a randomised controlled trial. Researchers reported the reduction in conduit harvest surgical site infections was statistically significant in the primary interrupted time series model, though a sensitivity analysis excluding the June 2025 transition month found the difference was no longer statistically significant.
Compliance Gains Among Urgent Cardiac Patients Drive the Operational Case for Steriwave Photodisinfection
A central finding highlighted in the announcement is the dramatic improvement in perioperative decolonisation compliance. Under the outpatient mupirocin protocol, overall compliance stood at 35.4%, falling to just 17.5% among urgent, non-elective patients who cannot complete multi-day pre-admission antibiotic regimens. Following transition to nurse-administered, point-of-care Steriwave treatment, compliance reached 93.3% across both elective and emergency cases. The announcement suggests this compliance barrier has historically undermined infection prevention efforts in high-acuity cardiac surgery, and the UOHI data indicates that a simplified point-of-care delivery model may offer an operational advantage in this patient population.
Secondary Outcomes and Statistical Limitations Noted in the UOHI Publication
The announcement also discloses secondary outcomes from the study. Total surgical site infections across the entire cohort declined from 9.1% before Steriwave implementation to 5.9% afterwards; however, this secondary outcome did not reach statistical significance. Sternal wound outcomes were described as directionally consistent but also not statistically significant. Ondine's Steriwave product is authorised in Canada and the UK but is not approved by the US Food and Drug Administration and remains limited to investigational use in the United States, representing a material regulatory risk investors should consider when assessing the commercial relevance of these published results.
Steriwave's Light-Activated Mechanism Addresses Antimicrobial Resistance Concerns in Surgical Decolonisation
Steriwave operates through a proprietary photosensitising agent activated by red light, producing an antimicrobial effect via oxidative mechanisms rather than conventional antibiotic pathways. Ondine states this non-antibiotic mode of action gives Steriwave a low potential for microbial resistance development — a clinically relevant distinction as antibiotic-resistant organisms remain a growing concern in hospital settings. Beyond nasal decolonisation, Ondine maintains a pipeline of photodisinfection products at various development stages targeting chronic sinusitis, ventilator-associated pneumonia, and burns, suggesting the UOHI publication may have broader implications for the company's clinical development strategy.




Please wait processing your request...